What is the ICD-10 code for paraganglioma, and should the patient be referred to rheumatology?

ICD-10 Code for Paraganglioma

The ICD-10 code for paraganglioma depends on the anatomic location: use D44.7 for extra-adrenal paragangliomas (including head/neck, thoracic, and abdominal locations), D35.0 for adrenal gland tumors (pheochromocytoma), or more specific codes like C75.4-C75.5 for malignant paragangliomas.

Coding Specificity

The ICD-10 coding system distinguishes paragangliomas by:

• Anatomic site: Head and neck paragangliomas (HNPGLs) vs. sympathetic paragangliomas vs. adrenal (pheochromocytoma)
• Behavior: Benign (D44.x series) vs. malignant (C75.x series)
• Specific location: Carotid body, jugular, vagal, aorticopulmonary, retroperitoneal, etc.

For billing and documentation purposes, specify the exact anatomic location when possible, as this impacts prognosis and management 1.

Rheumatology Referral Decision

No, you should NOT refer to rheumatology—paragangliomas are neuroendocrine tumors requiring endocrinology and surgical subspecialty management, not rheumatologic care.

Appropriate Referral Pathway

Refer to endocrinology as the primary specialist, with multidisciplinary involvement including:

1. Endocrinology (primary specialist for hormonal evaluation and genetic counseling)
2. Genetics for testing—up to 40% of paragangliomas are hereditary, particularly SDHx gene mutations 2, 3
3. Surgical subspecialists depending on location:
   • Otolaryngology/head and neck surgery for HNPGLs
   • Vascular surgery for carotid body tumors
   • Neurosurgery for skull base lesions
   • General/endocrine surgery for abdominal/adrenal tumors 4, 5

Why Endocrinology, Not Rheumatology?

Paragangliomas are catecholamine-secreting or non-functional neuroendocrine tumors arising from chromaffin cells 1, 2. They require:

• Biochemical screening: Plasma/urinary fractionated metanephrines and methoxytyramine 4, 6
• Functional imaging: 123I-MIBG scintigraphy, 18F-FDG PET, or 68Ga-DOTATATE PET 5
• Genetic testing: Particularly for SDHx, VHL, RET, NF1, and other susceptibility genes 2, 3
• Preoperative alpha-blockade if catecholamine-secreting 7, 5

These are all within endocrinology's scope, not rheumatology.

Critical Management Points

Genetic testing should be offered to ALL patients with paragangliomas 8, 6, particularly because:

• 40% have germline pathogenic variants 2, 4
• SDHD variants show 90-100% penetrance with paternal transmission 3
• Early detection through family screening reduces surgical complications 4
• Genetic background influences malignancy risk (SDHB has highest metastatic potential) 2, 3

Common pitfall: Only 35% of patients are actually referred for genetic testing despite guidelines recommending universal testing 8. Don't fall into this gap—refer for genetics evaluation regardless of age, family history, or tumor location.

Long-term Follow-up Requirements

After surgical resection, patients need:

• Annual biochemical screening (plasma/urinary metanephrines) for at least 10 years 6
• Lifelong follow-up for high-risk patients (young age, genetic disease, large tumors, paragangliomas vs. pheochromocytomas) 6, 5
• Surveillance imaging as clinically indicated 3, 9

This ongoing surveillance is managed by endocrinology, not rheumatology.